Biotech AssistantIndependent biopharma research
BIOTECH ASSISTANT / FIELD NOTES

BioNTech ends Phase 2 personalized mRNA monotherapy trial in resected colorectal cancer

Company / institutional announcement · BioNTech

Source published: · Event / reporting date: 2026-08-28

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What changed

BioNTech and Genentech decided to terminate BNT122-01, a Phase 2 trial of autogene cevumeran monotherapy after surgery in ctDNA-positive, high-risk stage II or stage III colorectal cancer. An independent board cited a numerical overall-survival imbalance and the low likelihood that continuing would change the efficacy outcome. No new product safety signals were identified; a pancreatic-cancer combination trial remains unaffected.

Why it may matter

This negative result informs patient selection and combination strategy without establishing that the same vaccine fails in other cancers or treatment combinations.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

mRNA / LNP

Related updates

Moderna / ACCESS Newswire

Moderna raises 2026 revenue outlook after third-quarter growth

Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.

mRNA / LNPAsk AI ↗
Ethris / GlobeNewswire

Ethris reports exploratory antiviral and exposure-response signals for nasal ETH47 in asthma

Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.

mRNA / LNP Clinical Pharmacology & Model-Informed DevelopmentAsk AI ↗
Moderna / ACCESS Newswire

Moderna reports initial mRNA-2808 T-cell engager results in multiple myeloma

Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.

mRNA / LNPAsk AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗